Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy

	Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy
刊名	CHINESE MEDICAL JOURNAL
	2016
卷号	129
关键词	PLATINUM-BASED CHEMOTHERAPY CELL LUNG-CANCER III COLON-CANCER THYMIDYLATE SYNTHASE ADJUVANT CHEMOTHERAPY PREDICTIVE-VALUE GASTRIC-CANCER LINK REPAIR ERCC1 EXPRESSION Colorectal Cancer Excision Repair Cross-complementation Group 1 Prognosis
ISSN号	0366-6999
其他题名	Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy
英文摘要	Background: Conflicting results about the association between expression level of excision repair cross-complementation group 1 (ERCC1) and clinical outcome in patients with colorectal cancer (CRC) receiving chemotherapy have been reported. Thus, we searched the available articles and performed the meta-analysis to elucidate the prognostic role of ERCC 1 expression in patients with CRC.
资助项目	[National High-Tech Research and Development Program of China (863 Program)]
语种	英语
CSCD记录号	CSCD:5650420
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/68191]
专题	中国科学院合肥物质科学研究院
推荐引用方式 GB/T 7714	. Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy[J]. CHINESE MEDICAL JOURNAL,2016,129.
APA	(2016).Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy.CHINESE MEDICAL JOURNAL,129.
MLA	"Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy".CHINESE MEDICAL JOURNAL 129(2016).